Abstract
In 1988, French pharmaceutical company Roussel Uclaf introduced Mifepristone (RU 486), a pill which medically induces abortion, but withdrew the drug one month later after severe protests. The abortion pill caused transnational controversies from 1988 to 1993. This article examines these controversies as a gateway to the entanglements between biomedical research, economic interests, and social protests in the last third of the twentieth century, as the American antiabortion movement initiated protests against the drug's French producer and its German parent company after its market release in France. The movement used boycotts against French products and utilized discomforting references to Germany's Nazi past to put pressure on pharmaceutical executives. In contrast, German, French, and American feminists and family-planners relied on transnational networks to enable medical trials and ensure the global distribution of Mifepristone. The article highlights how feminist demands for individual choice and public health concerns clashed with the antiabortion movements’ demands and entrepreneurs’ concerns about crude Holocaust comparisons. It shows that actors on both sides of the abortion controversy employed nonmedical arguments to influence scientific research and social movements acted on a transnational level to influence the market introduction of new biomedical advances.
Get full access to this article
View all access options for this article.